Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, and thank you for joining us for this session. I'm Paul Choi, and I cover the mid-cap biotech sector here at the firm. It's our pleasure to have Phathom Pharmaceuticals here joining us for this session. I think what we'll do is what we've done in prior sessions. I'll turn it over to Steve to my immediate left, to kick it off with maybe some high-level comments talk about what are Phathom's strategic priorities for the remainder of the year going into 2027.
We'll bring Sanjeev in also for Q&A later. And maybe after that, we'll go into questions.
Perfect. Thank you. Paul, thanks so much for the invitation to be here. It's a pleasure. Just a really high-level overview of the company, what we've done over the past year and where we're headed this year.
So Phathom has commercialized VOQUEZNA, which is the first-to-market PCAB to treat gastroesophageal reflux. We have approval for both erosive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
